Edition:
United States

People: Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

2.89USD
18 Apr 2019
Change (% chg)

$-0.01 (-0.34%)
Prev Close
$2.90
Open
$2.86
Day's High
$2.98
Day's Low
$2.84
Volume
98,323
Avg. Vol
95,683
52-wk High
$6.91
52-wk Low
$2.40

Knopf, Claude 

Mr. Claude Knopf serves as Senior Vice President, Chief Business Officer of the Company. Mr. Knopf is an accomplished executive in the biotech industry and brings to Pieris a demonstrable track record of success in strategy, corporate development, licensing, alliance management, marketing and sales spanning more than two decades. Prior to joining Pieris, Mr. Knopf served from July 2013 to July 2016 as Senior Vice President, Global Head Business Development & Licensing/Mergers and Acquisitions at Baxalta (formerly Baxter Bioscience) where through partnering and acquisitions he helped develop the Oncology business and pipeline and strengthened the Hematology and Immunology divisions. Prior to joining Baxalta, from 2001 to 2013 Mr. Knopf held several business development, alliance management, licensing and marketing roles at Novartis, most recently as the Head of Business Development and Licensing - Strategic Planning, Vaccines European Region. From 1995 until joining Novartis in 2001, Mr. Knopf also held several marketing, sales and finance positions at Merck Sharpe & Dohme. Mr. Knopf holds a Master of International Business Studies from the University of South Carolina, Moore School of Business and an BA in Economics from Manchester College.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --